Lv1
46 积分 2024-07-05 加入
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs
27天前
已完结
Discovery of a brain-penetrant fourth-generation EGFR inhibitor to overcome the human triple (L858R/T790 M/C797S) mutation
28天前
已完结
RET fusions in solid tumors
1个月前
已完结
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
1个月前
已完结
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
1个月前
已完结
BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice
1个月前
已完结
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)
1个月前
已完结
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study
1个月前
已完结
First-line treatment for advanced NSCLC in older patients and those with poor performance status
1个月前
已完结
Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer
1个月前
已完结
皖公网安备34019202002308
